Clinical Trial Update: Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial of regorafenib in combination with venetoclax and azacitidine for relapsed or refractory acute myeloid leukemia has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Stivarga (regorafenib) (regorafenib)
• Venclexa (venetoclax) (venetoclax)
• Vidaza (azacitidine) (azacitidine)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Status: SUSPENDED